Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises ALAFCO in connection with leasing of 4 brand new Airbus A320-NEO to SAS, delivered by Airbus from a production facility in Hamburg
Mandate

Vinge advises ALAFCO in connection with leasing of 4 brand new Airbus A320-NEO to SAS, delivered by Airbus from a production facility in Hamburg

February 03, 2021

Vinge has advised ALAFCO Aviation Lease and Finance Company, a Kuwait based, world leading operator in the airplane leasing business, in connection with the lease of 4 Airbus A320-NEOs, the new, more fuel-efficient narrow-body airplane, to Scandinavian Airlines System Denmark-Norway-Sweden (SAS).

Vinge has also managed the registration of all these new airplanes at the Swedish Transport Authority in the Aircraft Register and collaborated with international law firms as regards registration security rights in the International Aircraft Register which is maintained in Dublin according to the Cape Town Convention.

Vinge’s team consisted of partner, Fredrik Wilkens, together with Henrik Schön, Project Manager, as well as Anton Sjökvist and Elias Bohlin.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025